Current Antibiotic Options for the Treatment of Infections with AmpC-Producing Enterobacterales

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• AmpC beta-lactamases are enzymes produced by certain Enterobacterales.
• These enzymes confer resistance to key antibiotic classes, including third-generation cephalosporins and cephamycins.
• AmpC can be encoded on the chromosome or plasmids, influencing resistance patterns.

Purpose of the Study:

• To review the resistance mechanisms conferred by AmpC beta-lactamases.
• To discuss current and emerging therapeutic strategies for infections caused by AmpC producers.
• To highlight the need for further research in optimizing treatment.

Main Methods:

• Literature review of studies on AmpC beta-lactamases and antibiotic resistance.
• Analysis of treatment guidelines and clinical recommendations.
• Evaluation of the efficacy of various antibiotic classes against AmpC producers.

Main Results:

• Third-generation cephalosporins are generally avoided for high-risk AmpC producers.
• Cefepime and carbapenems are preferred for severe infections.
• Non-beta-lactam agents (fluoroquinolones, trimethoprim-sulfamethoxazole, aminoglycosides) are viable if susceptible.
• Newer agents like beta-lactam/beta-lactamase inhibitors and cefiderocol show activity but are often reserved for co-infections with carbapenemases.

Conclusions:

• Optimal treatment for AmpC-producing Enterobacterales requires careful antibiotic selection.
• Current strategies involve avoiding certain cephalosporins and utilizing alternatives like cefepime or carbapenems.
• Further prospective studies are essential to clarify the best therapeutic approaches.